Author:
Pearce C L, ,Wu A H,Gayther S A,Bale A E,Beck P A,Beesley J,Chanock S,Cramer D W,DiCioccio R,Edwards R,Fredericksen Z S,Garcia-Closas M,Goode E L,Green A C,Hartmann L C,Hogdall E,Kjær S K,Lissowska J,McGuire V,Modugno F,Moysich K,Ness R B,Ramus S J,Risch H A,Sellers T A,Song H,Stram D O,Terry K L,Webb P M,Whiteman D C,Whittemore A S,Zheng W,Pharoah P D P,Chenevix-Trench G,Pike M C,Schildkraut J,Berchuck A
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Agoulnik IU, Tong XW, Fischer DC, Korner K, Atkinson NE, Edwards DP, Headon DR, Weigel NL, Kieback DG (2004) A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab 89: 6340–6347
2. Akahira J, Inoue T, Suzuki T, Ito K, Konno R, Sato S, Moriya T, Okamura K, Yajima A, Sasano H (2000) Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br J Cancer 83: 1488–1494
3. Auranen A, Song H, Waterfall C, Dicioccio RA, Kuschel B, Kjaer SK, Hogdall E, Hogdall C, Stratton J, Whittemore AS, Easton DF, Ponder BA, Novik KL, Dunning AM, Gayther S, Pharoah PD (2005) Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer 117: 611–618
4. Berchuck A, Schildkraut JM, Wenham RM, Calingaert B, Ali S, Henriott A, Halabi S, Rodriguez GC, Gertig D, Purdie DM, Kelemen L, Spurdle AB, Marks J, Chenevix-Trench G (2004) Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiol Biomarkers Prev 13: 2141–2147
5. Cooper GS, Schildkraut JM, Whittemore AS, Marchbanks PA (1999) Pregnancy recency and risk of ovarian cancer. Cancer Causes Control 10: 397–402